Conference Coverage

Remibrutinib safe for Sjögren’s in phase 2


 

AT ACR 2022

Nearly 4 million in U.S. live with the disease

Nearly 4 million people in the United States live with the disease. Common symptoms include light sensitivity, dry eye, dry mouth, fatigue, and joint pain.

SS can be difficult to diagnose because the symptoms vary from person to person and can be confused with those caused by other diseases.

Ardy Fenando, MD, a rheumatology fellow with the University of Kansas Medical Center, said in an interview, “We need more therapies for Sjögren’s. Heterogeneity complicates the way we set the primary endpoints. Therefore, we haven’t had a proven treatment for Sjögren’s. This is supported by previous RCTs [randomized controlled trials] that failed to meet the primary end points.”

Dr. Dörner has relationships with AbbVie, Eli Lilly, Roche/Genentech, Janssen, Novartis, Bristol-Myers Squibb), and UCB. Other authors have various relationships with industry. Dr. Fenando and Dr. Dobrowolski have disclosed no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Cell-killing cancer therapy treats lupus successfully
MDedge Rheumatology
Hormones’ impact described in transgender rheumatology patients
MDedge Rheumatology
Breakthrough COVID studies lend support to use of new boosters in immunosuppressed patients
MDedge Rheumatology
Evusheld PrEP may protect immunocompromised patients from severe COVID-19
MDedge Rheumatology
IVIG proves effective for dermatomyositis in phase 3 trial
MDedge Rheumatology
Metabolites may distinguish severe subtypes of PAH
MDedge Rheumatology
Rheumatic diseases and assisted reproductive technology: Things to consider
MDedge Rheumatology
First recommendations for cancer screening in myositis issued
MDedge Rheumatology
Clinical signs differ between children and adults with vasculitis
MDedge Rheumatology
Rituximab ‘a reasonable alternative to cyclophosphamide’ to improve ILD-CTD
MDedge Rheumatology